Ocrelizumab not checked

Roche · RO4964913 · PRO70769

FollowEvery change as it happens, and a Monday email
Stage
in the US · approved in the EU
Next date
Phase 4 trial completes
Trials
21 active
37 in total · 22 in the EU
Targets
 

What this is

How it works
An antibody that marks B cells (a type of immune cell) for destruction. Used in blood cancers and autoimmune disease.CD20-directed Cytolytic Antibody FDA class
How it’s given
“Ocrelizumab will be administered as per the schedule specified in the respective arms.”In the company’s words, NCT07483450 on ClinicalTrials.gov
Tested for
Multiple Sclerosis (8 trials), Multiple Sclerosis, Primary Progressive (2 trials), Relapsing-remitting Multiple Sclerosis (2 trials), Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Progressive Multiple Sclerosis (PMS), Progressive Multiple Sclerosis
Main trialPhase 4
“The main purpose of this study is to evaluate the efficacy of ocrelizumab in participants with relapsing multiple sclerosis (RMS) and to characterize the ocrelizumab pharmacodynamic (PD) profile in Chinese participants with primary progressive multiple sclerosis (PPMS).”In the company’s words, NCT07483450 on ClinicalTrials.gov
Other names
Ocrevus · RO4964913 · OCR · PRO70769 · rhuMAb 2H7
Given with
Avonex (Biogen)Other companies’ drugs in its trials

Other drugs for Multiple Sclerosis

All 54 drugs for Multiple Sclerosis

Copies tested against it3

Other companies’ versions, mostly cheaper copies for when the patent ends

Coming up6

Changes1

Last 90 days

Trials37

TrialPhaseCompletesWhat it tests
Phase 4Active, not recruiting 31 Dec 2027 A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Participants With Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis
Phase 4Recruiting 28 Feb 2029 A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy
Phase 3Active, not recruiting 19 Dec 2024 A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)
Phase 3Active, not recruiting 15 Jan 2025 A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis
Phase 3Active, not recruiting 9 Jun 2025 A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)
Phase 3Active, not recruiting 30 Jun 2025 A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)
Phase 3Active, not recruiting 17 Sep 2025 A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis
Phase 3Active, not recruiting 22 Oct 2026 A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis
Phase 3Active, not recruiting 31 Dec 2027 A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis
Phase 3Recruiting 31 Dec 2029 An Extension Study to Assess Impact of Multiple Sclerosis (MS) on Physical Function and Provide Continued Ocrelizumab Treatment
Phase 2Active, not recruiting 5 Oct 2023 A Study of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis
Phase 2Active, not recruiting 17 Sep 2026 A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)
Phase 2Recruiting 30 May 2028 A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)
Phase 2Not yet recruiting 31 Aug 2029 A Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous Ocrelizumab Administration in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)
Phase 1Active, not recruiting 1 Sep 2026 A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of a New Subcutaneous Formulation of Ocrelizumab in Participants With Multiple Sclerosis
Phase 4Completed 15 Feb 2021 A Study to Provide Complementary Efficacy, Safety and Patient Reported Outcomes Data in Participants With Active Relapsing Forms of Multiple Sclerosis (MS) in a Pragmatic Setting
Phase 4Completed 15 Dec 2022 Prospective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With Ocrelizumab
Phase 4Completed 29 Mar 2024 A Study Evaluating B Cell Levels In Infants Of Lactating Women With CIS Or MS Receiving Ocrelizumab
Phase 4Completed 8 Apr 2024 A Study Evaluating B Cell Levels In Infants Potentially Exposed To Ocrelizumab During Pregnancy
Phase 4Withdrawn 31 Jan 2025 A Study To Determine The Effect Of Ocrelizumab On Leptomeningeal Inflammation In Multiple Sclerosis
Phase 3Completed 2 Apr 2015 A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis
Phase 3Completed 12 May 2015 A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis
Phase 3Completed 23 Jul 2015 A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis
Phase 3Completed 14 Feb 2017 A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis
Phase 3Completed 25 Oct 2019 A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
Phase 3Completed 10 Mar 2023 A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis
Phase 3Completed 11 Apr 2023 Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS)
Phase 3Terminated 27 Apr 2023 Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS)
Phase 3Completed 17 Jul 2025 This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS)
Phase 2Completed 9 Mar 2012 A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis
Phase 1Completed 3 Jun 2025 A Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Participants With Multiple Sclerosis
Phase 3Authorised not given For patients with active multiple sclerosis, impact of annual versus semi-annual infusions of ocrelizumab after 2 years of initial treatment on the absence of radiological disease activity at 2 years: a multicentre randomised controlled non-inferiority trial
Phase 3Authorised not given Ocrelizumab VErsus Rituximab off-Label at the Onset of Relapsing MS Disease (OVERLORD-MS)
Phase 3/4Authorised not given Efficacy, safety and cost-effectiveness of B cell tailored ocrelizumab versus standard ocrelizumab in relapsing remitting multiple sclerosis (BLOOMS): a randomized controlled trial
Phase 4Authorised not given The use of therapeutic monitoring of ocrelizumab serum concentrations for personalized pharmacotherapy of relapsing-remitting and primary progressive multiple sclerosis
Phase 3Authorised not given STOP-I-SEP_Disease modifying therapies withdrawal in inactive Secondary Progressive Multiple Sclerosis patients older than 50 years
Phase 3Authorised not given A PHASE III, OPEN-LABEL, SINGLE-ARM, MULTI-CENTER STUDY TO EVALUATE THE SAFETY AND USE OF AN ON-BODY DELIVERY SYSTEM FOR THE SUBCUTANEOUS HOME ADMINISTRATION OF OCRELIZUMAB IN PATIENTS WITH MULTIPLE SCLEROSIS
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Ocrelizumab

Following is part of Solo: you see every change to Ocrelizumab the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in